BFA
MACK

BlackRock Fund Advisors’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

BlackRock Fund Advisors’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$27.9M Buy
869,083
+77,667
+10% +$3.31M 0.01% 1993
2016
Q3 		$39.5M Buy
791,416
+75,118
+10% +$3.12M 0.01% 1732
2016
Q2 		$30.4M Buy
716,298
+44,772
+7% +$2.44M 0.01% 1796
2016
Q1 		$44.2M Buy
671,526
+2,764
+0.4% +$144K 0.01% 1529
2015
Q4 		$41.6M Buy
668,762
+5,073
+0.8% +$357K 0.01% 1598
2015
Q3 		$44.4M Sell
663,689
-1,794
-0.3% -$146K 0.01% 1493
2015
Q2 		$64.7M Buy
665,483
+32,389
+5% +$3.08M 0.02% 1348
2015
Q1 		$59.2M Buy
633,094
+29,920
+5% +$2.55M 0.01% 1408
2014
Q4 		$53.6M Buy
603,174
+51,389
+9% +$3.74M 0.01% 1418
2014
Q3 		$38.1M Buy
551,785
+17,492
+3% +$935K 0.01% 1540
2014
Q2 		$30.6M Buy
534,293
+69,236
+15% +$3.52M 0.01% 1742
2014
Q1 		$18.4M Buy
465,057
+14,580
+3% +$624K 0.01% 2044
2013
Q4 		$18.9M Sell
450,477
-8,085
-2% -$234K 0.01% 2019
2013
Q3 		$13.7M Buy
458,562
+84,104
+22% +$2.94M ﹤0.01% 2173
2013
Q2 		$19.9M Buy
+374,458
New +$16.4M 0.01% 1862

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
TA
Teachers Advisors New York $81.7B AUM 13.62% 1-Year Est. Return

BlackRock Fund Advisors's MACK Position: Q4 2016 in Review

BlackRock Fund Advisors increased its Merrimack Pharmaceuticals, Inc. (MACK) stake by 9.8% in Q4 2016, buying an estimated $3.31M and bringing the position to 869,083 shares worth $27.9M. The position accounts for 0.01% of the portfolio, ranked #1993.

BlackRock Fund Advisors first reported a position in MACK in Q2 2013 and has held it in 15 quarters since. The position peaked at $64.7M in Q2 2015. 136 funds tracked by Wall St. Rank hold MACK as of Q4 2016.

  • BlackRock Fund Advisors held 869,083 shares of Merrimack Pharmaceuticals, Inc. worth $27.9M as of Q4 2016.
  • BlackRock Fund Advisors bought 77,667 Merrimack Pharmaceuticals, Inc. shares in Q4 2016, an estimated $3.31M.
  • Merrimack Pharmaceuticals, Inc. made up 0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #1993 holding.
  • BlackRock Fund Advisors first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2013 and has held it in 15 quarters since.
  • BlackRock Fund Advisors's Merrimack Pharmaceuticals, Inc. position peaked at $64.7M in Q2 2015.
  • 136 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.